Is Ibogaine Legal in the US? Federal, Texas and FDA Status as of 2026-10-26

Is ibogaine legal in the United States?

Ibogaine is not legal for use in the United States because federal law lists it as a Schedule I controlled substance.

The listing is in 21 CFR 1308.11(d)(21) under DEA code 7260. Schedule I means no currently accepted medical use under federal law. Researchers can handle it with a DEA registration. A clinic, retreat or individual cannot lawfully offer it as treatment.

Federal law also sits above state law on this point. No US state has made ibogaine available for general medical use, as far as the sources checked for this page show. State actions so far fund or authorize research.

This page reports law in force, agency actions and proposals separately, and dates each one as of 2026-10-26. It is not legal or medical advice. A lawyer can tell you how the law applies to a specific act.

Ibogaine legal status tracker, as of 2026-10-26

The table below lists each ibogaine item that people cite as a sign of legalization, with what it is and what it does not change.

Item	What it says	Status type	Source
Federal schedule	Ibogaine is Schedule I, code 7260	Law in force	eCFR
FDA RFI, Docket FDA-2026-N-10429	Describes approaches FDA is considering for early-phase trials; comments close Nov 20, 2026	Agency action (request for information, not a rule)	Federal Register
Noribogaine study	FDA allowed an early-phase study of an ibogaine derivative on Apr 24, 2026	Agency action (IND allowed, not approval)	FDA
Federal research funding	HHS funds ibogaine trials through ARPA-H and NIDA	Funding program	Federal Register
DEA registration notice	Groff Health Inc applied on Sep 3, 2026 to bulk manufacture ibogaine and other Schedule I substances	Application notice (no decision stated)	Federal Register
Texas SB 2308	Funds FDA-supervised ibogaine trials; $50 million cannot be disbursed until a non-state match arrives	Law in force; funding blocked as reported Oct 8, 2026	Center Square
Colorado HB 26-1325	Creates an ibogaine research pilot of up to five sites, contingent on gifts, grants or donations	Law in force since Aug 12, 2026	Colorado General Assembly
Other state bills	Kentucky, Mississippi, Arizona and Washington funding measures appear on advocacy trackers	Not verified against legislature sites	None checked

The last row is a gap, not a finding. This page did not confirm those four states against official legislative records, so it does not report their status.

What is the FDA ibogaine request for information?

The FDA ibogaine request for information is a public notice asking for comments on how early-phase ibogaine trials should be designed and monitored.

FDA announced it on October 5, 2026, and the Federal Register published it on October 6 as Docket No. FDA-2026-N-10429. Comments close at 11:59 p.m. Eastern on November 20, 2026. That gives a 45-day window from publication, with 25 days left as of October 26.

The notice says HHS is funding clinical development and that the first federally supported trials are expected to enroll adults with opioid use disorder and adults with PTSD. FDA also says the notice “does not establish legally enforceable requirements or regulatory expectations” and is not its final view.

It does not approve ibogaine, change the schedule or allow anyone to use it outside a trial. FDA may later issue guidance or take other action after reading the comments.

What heart-safety questions did FDA raise about ibogaine?

FDA asked how an early-phase ibogaine trial can monitor for QTc prolongation, a heart rhythm change that can lead to a life-threatening arrhythmia called torsades de pointes.

FDA’s own summary of the risk is direct. It says clinical data show ibogaine “commonly causes substantial QTc interval prolongation,” linked to dangerous rhythms and death. It also cites animal studies reporting brain toxicity at higher doses and says dose and product quality are poorly characterized in the published literature.

The notice describes one possible design, not a rule. In plain terms:

• Setting: an inpatient unit able to treat a life-threatening arrhythmia, with continuous rhythm monitoring, a defibrillator at the bedside, emergency pacing and a physician-led team trained in advanced cardiac life support.
• Length of monitoring: from dosing until rhythms are normal and QTc is near its starting value, which FDA says could take up to 36 hours. Participants might stay at least 36 hours and leave after a 48-hour ECG without QTc prolongation.
• Who could enroll: adults 18 to 55 who have stopped psychiatric medicines. Likely exclusions include a baseline QTcF of 430 ms or more, structural heart disease, and a personal or family history of arrhythmia or sudden cardiac death.
• Medicines to stop first: those that lengthen QTc, slow the heart, interact with the CYP2D6 enzyme or raise serotonin. FDA names methadone, buprenorphine, antipsychotics, antiemetics and SSRIs as examples.
• Stopping rules: pause dosing for a sustained ventricular arrhythmia, a seizure, or QTc above 500 ms lasting more than two days.
• Dosing: a single dose, in small groups with rising doses, not exceeding 10 mg/kg. FDA notes published reports used 5 to 20 mg/kg and says those doses lack adequate safety margins in animal data.
• Oversight: a safety committee with a cardiologist, plus an independent board with a cardiologist, neurologist, psychiatrist and biostatistician.

FDA points to ibutilide, an approved heart drug that causes torsades de pointes in about 1.7 percent of patients and needs at least four hours of continuous ECG monitoring. It says ibogaine likely needs longer because its active metabolite, noribogaine, clears slowly.

FDA also cites a prospective study of people with opioid use disorder given a single 10 mg/kg dose, in which all participants had severe but transient ataxia (loss of balance and coordination). Whether ibogaine causes lasting nerve or cognitive injury in humans has not been studied systematically, according to the notice.

These are trial-design ideas for research teams. They are not a protocol for anyone to follow on their own. A person with heart disease or on QT-prolonging medicines should speak to a physician before considering any ibogaine study or treatment.

Is ibogaine legal in Texas now?

Ibogaine is not legal for use in Texas, and Texas Senate Bill 2308 only funds FDA-supervised research.

Governor Greg Abbott signed SB 2308 in 2025, according to KSAT’s report of the Texas Tribune story. The Legislature approved $50 million. In December 2025 the Health and Human Services Commission picked UTHealth Houston, with UTMB, to lead the trials, per The Center Square.

The money is stuck. Section 491.055(d) of the Health and Safety Code says the commission “may not disburse funds” until matching funds arrive “from sources other than the state,” as quoted in that report. The Center Square says no drug company submitted a qualifying proposal, and Texas leaders said on March 31, 2026 that they intended to fund the program in full.

A federal match is possible but unsettled. The report says HHS directed at least $50 million through ARPA-H’s EVIDENT initiative to “match state government investments in psychedelic research,” and that ARPA-H had not spent any of it. A researcher at Rice University’s Baker Institute told the outlet that federal money could satisfy the statute but may stray from its intent. As of the October 8 report, it was not clear whether Texas had applied.

This page did not open the statute or the HHSC program page directly, because those state sites did not load. Treat the Texas details as press-reported until checked against the Texas Legislature and HHSC.

Why state funding and Right to Try do not make ibogaine legal

State research funding and Right to Try laws do not make ibogaine legal because neither one removes ibogaine from federal Schedule I.

State funding. A state can pay for a trial. It cannot change the federal schedule. Colorado’s HB 26-1325 shows the pattern: it creates a pilot of up to five sites, makes the pilot depend on gifts, grants or donations, and tells the state to seek ARPA-H money. The bill text summary lists no dollar appropriation. Texas funds a trial under an FDA application. Neither makes ibogaine available at a clinic.

Right to Try. The federal Right to Try law covers an “eligible investigational drug.” One condition is that a Phase 1 clinical trial has been completed. FDA’s October 2026 notice describes the first federally supported ibogaine trials as still expected, so this page found no ibogaine product that meets the condition. The law also sits beside the Controlled Substances Act. In a psilocybin case, the Ninth Circuit ruled on February 13, 2025 that a doctor still needed DEA registration, according to a law-firm summary. This page did not read the opinion itself, so treat that as a secondary account.

The same reasoning applies to the April 24, 2026 noribogaine study. FDA’s release said allowing it “does not mean the drug has been approved or found to be safe or effective.”

When will ibogaine be legal in the USA?

No agency has published a date for ibogaine approval or rescheduling, and none of the sources checked for this page give one.

The steps are known even if the timing is not. FDA must find a drug safe and effective for its labeled use before approval, as its notice explains under section 505(d) of the Food, Drug, and Cosmetic Act. Ibogaine is at the start of that path. FDA says data from the federally funded trials “may support future later-stage studies.”

Watch these dated items instead of forecasts:

• November 20, 2026: FDA comment docket closes.
• Any FDA guidance that follows the docket, which FDA says it may issue.
• Texas reporting on whether the non-state match is met.
• DEA decisions on Schedule I research registrations such as the Groff Health application noticed on October 19, 2026.

A clinic or advocacy page that gives a 2027 or 2028 date is offering its own estimate. For other substances and states, see the Psychedelic Status guides, and for how each status is checked, read how we research.

What about ibogaine treatment abroad?

Ibogaine treatment abroad is a separate legal question from US law, and this page does not cover it.

Many top search results for this topic are clinic or rehab sites that steer readers toward treatment in other countries. Rules, licensing and medical standards vary by country, and FDA’s notice describes the heart-monitoring setting it considers necessary for a trial. If you are weighing any clinic, ask what cardiac screening and monitoring it provides and what emergency care is on site, and talk to your own physician first.